The historical rank and industry rank for BioLife Solutions's Net Margin % or its related term are showing as below:
BLFS'
s Net Margin % Range Over the Past 10 Years
Min: -183.38 Med: -24.93 Max: 4.12
Current: -2.97
BLFS's Net Margin % is ranked worse than 57.28% of 817
companies
in the Medical Devices & Instruments industry
Industry Median: 2.09
vs BLFS: -2.97
BioLife Solutions (NAS:BLFS) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
BioLife Solutions Net Margin % Related Terms
BioLife Solutions Net Margin % Historical Data
* Premium members only.
The historical data trend for BioLife Solutions's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, BioLife Solutions's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioLife Solutions Net Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, BioLife Solutions's Net Margin % distribution charts can be found below:
* The bar in red indicates where BioLife Solutions's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioLife Solutions (BLFS) has a Net Margin % of 4.31% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on BioLife Solutions and its competitors. According to the industry distribution chart, BioLife Solutions ranks #468 out of 817 companies in the Medical Devices & Instruments industry, placing it in the top 57.3%.
Is BioLife Solutions' Net Margin % too high?
BioLife Solutions' current Net Margin % is 4.31%. The Medical Devices & Instruments industry median Net Margin % is 2.09. BioLife Solutions' value of 4.31% is 106.2% above this industry median. Based on the distribution chart, BioLife Solutions ranks #468 out of 817 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, BioLife Solutions has a GF Score™ of 72/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does BioLife Solutions' Net Margin % compare to KMTS and AZTA?
According to the Medical Devices & Instruments industry distribution chart, BioLife Solutions ranks #468 out of 817 companies for Net Margin %. This places BioLife Solutions in the lower half of its industry. The industry median Net Margin % is 2.09. BioLife Solutions' value of 4.31% is 106.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Medical Devices & Instruments company?
The median Net Margin % among Medical Devices & Instruments companies is 2.09, based on 817 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioLife Solutions's current Net Margin % of 4.31% is 106.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on BioLife Solutions and its competitors. For the Medical Devices & Instruments industry, the median Net Margin % is 2.09 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioLife Solutions's current Net Margin % is 4.31%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioLife Solutions stock overvalued right now?
Based on GuruFocus' analysis, BioLife Solutions (BLFS) is currently considered Fairly Valued. The stock's GF Value™ is $28.57, compared to a current price of $28.64 — trading 0.2% above its estimated fair value. The current Net Margin % is 4.31% and 106.2% above the Medical Devices & Instruments industry median of 2.09. BioLife Solutions' overall GF Score™ is 72/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For BioLife Solutions (BLFS), the current Net Margin % is 4.31% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioLife Solutions (BLFS) Overvalued in 2026?
Based on GuruFocus' analysis, BioLife Solutions stock appears to be overvalued.
The current stock price of $28.64 is trading 0.2% above its estimated GF Value™ of $28.57.
GuruFocus considers BioLife Solutions to be Fairly Valued.
Key valuation signals for BLFS:
Net Margin %: 4.31%
GF Value™: $28.57 vs. price of $28.64 (0.2% above fair value)
Industry Position: 106.2% above the Medical Devices & Instruments median (#468 of 817)
No single metric tells the full story. See the BLFS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioLife Solutions Inc is a life sciences company that develops, manufactures, and markets bioproduction products and services that are designed to improve quality and de-risk biologic manufacturing, distribution, and transportation in the cell and gene therapy ("CGT") industry. The company provides solutions such as Cell Processing, Cold Chain, and Thawing. The company generates the majority of its revenue from Cell Processing through the biopreservation product "CryoStor". Geographically the company generates the majority of its revenue from the United States.
72GF Score
Get the complete analysis for BLFS
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BLFS has been successfully added to your 
